contemporari
drug
discoveri
effort
aim
modul
activ
specif
target
almost
alway
protein
essenti
pathogen
human
protein
misregul
misfold
mutat
identif
chemic
lead
target
key
step
drug
discoveri
process
startingpoint
chemic
lead
includ
natur
product
high
throughput
screen
ht
larg
chemic
librari
recent
fragmentbas
drug
discoveri
fbdd
latter
method
evolv
past
year
gener
high
affin
ligand
serv
start
point
develop
drug
candid
fbdd
approach
util
compound
lower
molecular
weight
da
compar
use
highthroughput
screen
origin
fbdd
debat
document
xray
crystallographi
first
use
map
interact
smallmolecul
organ
solvent
eg
acetonitril
isopropanol
protein
surfac
shuker
cowork
describ
sar
nmr
nmr
use
map
small
organ
molecul
subsit
protein
follow
optim
link
entiti
produc
highaffin
ligand
stout
cowork
demonstr
addit
natur
substrat
fragment
crystal
structur
thymidyl
synthas
complex
fragment
deoxyuridin
monophosph
suggest
modular
approach
lead
design
small
organ
molecul
refer
fragment
bind
element
needl
shape
seed
templat
notabl
approach
use
fbdd
success
larg
ht
screen
fail
exampl
develop
bace
inhibitor
fbdd
differ
respect
establish
ht
sever
aspect
divers
chemic
function
sampl
rel
volum
chemic
space
greater
fragment
give
elev
hitrat
compar
ht
ligand
becom
complex
probabl
observ
relev
interact
fall
dramat
given
librari
consequ
higher
chemic
divers
better
hitrat
fragment
librari
tend
smaller
size
order
compound
compar
librari
larger
compound
use
ht
may
contain
compound
smaller
size
fragment
librari
compar
ht
librari
make
fbdd
access
small
biotechnolog
compani
academ
laboratori
access
larg
compound
librari
fragment
tend
low
affin
target
compar
ht
hit
fragmentscreen
techniqu
need
suffici
sensit
detect
hit
kd
valu
mm
high
rang
low
affin
partli
consequ
overcom
rigid
bodi
entrop
barrier
estim
kjmol
order
magnitud
kd
k
effect
independ
molecular
weight
thu
fragment
overcom
barrier
form
high
qualiti
interact
highli
energet
favor
interact
overcom
entrop
cost
bind
fragment
often
bind
better
ligand
effici
le
tradit
screen
hit
le
function
bind
free
energi
number
heavi
atom
nha
system
le
import
aspect
optim
process
fragment
develop
lead
high
qualiti
interact
maintain
thu
matur
lead
compound
possibl
see
moieti
fragment
lead
grew
earli
fbdd
project
util
crystallographi
nmr
method
primari
screen
method
valid
hit
vital
compon
fbdd
strategi
includ
techniqu
estim
bind
affin
isotherm
titrat
calorimetri
itc
consid
gold
standard
valid
itc
highli
sensit
use
determin
enthalp
entrop
contribut
fragment
bind
free
energi
boehm
cowork
use
silico
screen
follow
valid
biophys
method
includ
nmr
target
dna
gyras
recent
thermal
shift
assay
tsa
surfac
plasmon
reson
spr
employ
review
shall
address
practic
consider
fb
crystallographi
provid
exampl
use
success
drug
discoveri
program
highlight
case
complementari
approach
assist
discoveri
process
potenti
pitfal
lead
compound
must
high
affin
target
drug
like
physicochem
pharmacodynam
properti
lipinski
cowork
identifi
key
featur
oral
bioavail
drug
call
rule
five
molecular
weight
da
calcul
log
partit
coeffici
octanol
water
clogp
measur
lipophil
number
hydrogen
bond
donor
number
hydrogen
bond
acceptor
congrev
cowork
analyz
divers
set
fragment
hit
rang
target
develop
socal
rule
three
molecular
weight
da
clogp
number
hydrogenbond
donor
number
hydrogenbond
acceptor
fragment
librari
design
function
group
divers
mind
reactiv
potenti
toxic
function
group
unsuit
drug
exclud
fragment
librari
tend
bias
toward
planar
achir
heterocycl
argu
recent
use
fragment
richer
result
increas
hit
distinct
site
biolog
target
size
estim
chemic
space
vari
greatli
depend
criteria
use
earli
studi
size
chemic
space
ie
number
possibl
molecul
druglik
properti
estim
high
compound
recent
much
lower
estim
base
powerfunct
deriv
growth
organ
compound
function
number
carbon
atom
put
size
chemic
space
druglik
compound
carbon
atom
fink
reymond
estim
number
chemic
entiti
c
n
f
atom
follow
congrev
rule
three
million
owe
inher
weak
bind
fragment
need
solubl
mm
crystal
soak
buffer
stock
solut
dimethylsulfoxid
dmso
improv
effici
fragment
soak
cocktail
contain
multipl
compound
use
number
fragment
cocktail
dictat
requir
concentr
concentr
dmso
toler
crystal
sever
commerci
fragment
librari
suitabl
crystallograph
screen
avail
zenobia
therapeut
san
diego
ca
http
wwwzenobiatherapeuticscom
distribut
two
set
compound
librari
compound
librari
compound
maybridg
cornwal
uk
http
wwwmaybridgecom
distribut
rule
divers
fragment
librari
consist
core
set
compound
supplement
set
compound
otava
kyiv
ukrain
http
wwwotavachemicalscom
suppli
fragment
librari
set
compound
chembridg
san
diego
ca
http
wwwchembridgecom
distribut
compound
fragment
librari
librari
use
aforement
rule
three
criteria
sever
case
addit
proprietari
filter
shape
chemistri
librari
develop
inform
suppli
librari
vari
supplier
gener
includ
chemic
structur
smile
string
threedimension
structur
file
import
requir
crystallograph
fb
avail
target
protein
crystal
structur
solut
avail
crystal
must
robust
stabl
soak
condit
diffract
beyond
place
fragment
unambigu
electron
densiti
crystal
still
repres
signific
bottleneck
structur
determin
xray
diffract
techniqu
today
techniqu
tool
avail
aid
crystal
difficult
target
autom
form
robot
platebas
screen
techniqu
microfluid
platform
allow
mani
condit
sampl
econom
use
submicrolit
volum
sampl
furthermor
techniqu
molecular
biolog
protein
chemistri
includ
modif
target
enzym
see
protein
engin
aid
crystal
difficult
target
protein
produc
natur
recombin
express
may
contain
flexibl
disord
region
hinder
format
crystal
contact
possibl
includ
n
ctermin
region
intern
loop
posttransl
modif
eg
mani
eukaryot
protein
undergo
n
oglycosyl
remov
flexibl
heterogen
glycosid
group
improv
crystalliz
wellestablish
strategi
numer
deglycosyl
enzym
commerci
avail
success
strategi
outlin
use
proteas
form
stabl
fragment
protein
crystal
recent
proteolysi
situ
addit
trace
amount
trypsin
chymotrypsin
report
case
flexibl
loop
termini
potenti
block
crystal
contact
proteas
remov
strategi
may
fail
due
incomplet
proteolysi
lead
sampl
heterogen
protein
target
obtain
heterolog
overexpress
protein
crystalliz
improv
protein
engin
altern
proteolysi
identifi
minim
function
fragment
target
design
modifi
gene
overexpress
protein
crystalliz
often
hamper
poor
solubl
target
protein
strategi
replac
hydrophob
residu
may
increas
propens
protein
aggreg
hydrophil
one
lead
diffractionqu
crystal
solubl
catalyt
domain
integras
improv
singl
multiplepoint
mutat
hydrophob
residu
mutant
singl
hydrophob
amino
acid
target
chang
lysin
mutant
two
three
hydrophob
amino
acid
chang
simultan
conserv
substitut
alanin
made
work
singlepoint
mutant
show
dramat
improv
solubl
yield
xrayqual
crystal
free
surfac
cystein
residu
may
also
interfer
crystal
oxid
format
intramolecular
disulfid
bond
mutat
cystein
residu
less
reactiv
serin
enhanc
crystalliz
crystal
human
achiev
part
strategi
wherebi
initi
model
creat
base
homolog
structur
six
cystein
residu
predict
lie
surfac
mutat
serin
patel
cowork
use
sever
experiment
approach
includ
chemic
modif
crystallographi
show
free
cystein
residu
mitogenactiv
protein
kinas
prone
modif
result
mutant
prepar
show
improv
homogen
stabil
gave
improv
crystal
fragment
screen
crystal
typic
soak
cocktail
contain
compound
see
composit
cocktail
chosen
contain
distinct
shape
unambigu
defin
electron
densiti
hit
rate
less
one
compound
per
cocktail
avoid
ambigu
electron
densiti
result
multipl
hit
bound
partial
occup
compound
may
caus
crystal
crack
dissolv
risk
crystal
damag
increas
number
differ
compound
cocktail
appropri
strategi
sensit
crystal
keep
number
fragment
cocktail
low
badger
describ
practic
consider
crystal
prepar
soak
cryoprotect
structur
refin
electron
densiti
interpret
synchrotron
radiat
robot
crystal
mount
data
collect
offer
signific
advantag
crystallograph
fragment
screen
synchrotron
beamlin
macromolecular
crystallographi
widespread
beamlin
avail
worldwid
http
biosyncsbkborg
sever
pharmaceut
interest
oper
dedic
beamlin
lilli
research
laboratori
collabor
access
team
lrlcat
advanc
photon
sourc
argonn
illinoi
describ
detail
intens
synchrotron
xradiat
facilit
short
data
collect
time
necessit
fastreadout
detector
robot
samplechang
increas
data
collect
effici
popular
detector
synchrotron
util
chargecoupl
devic
ccd
technolog
commonli
use
ccd
manufactur
area
detector
system
corpor
usa
marresearch
germani
emerg
technolog
diffract
data
measur
pixel
array
detector
pad
made
twodimension
array
pn
diod
join
readout
chip
pad
enabl
readout
time
less
millisecond
compar
ccd
beamlin
esrf
featur
pilatu
pad
mm
detector
featur
pixel
ms
readout
time
capabl
record
frame
per
second
concomit
deploy
robot
system
crystal
handl
develop
control
autom
softwar
socal
datacollect
pipelin
dcp
autom
procedur
robot
sampl
mount
product
reflect
data
readi
structur
elucid
robot
system
sampl
chang
synchrotron
beamlin
includ
stanford
autom
mounter
sam
system
rigaku
carlsbad
ca
usa
al
automount
common
featur
system
use
special
cassett
sampl
storag
ship
robot
handl
way
exampl
sam
allow
crystal
screen
without
human
intervent
sampl
pin
hold
crystal
mount
cylindr
cassett
contain
port
robot
access
three
cassett
one
time
synchrotron
beamlin
util
sam
sampl
changer
diffract
experi
data
collect
run
control
synchrotron
remot
use
bluicedistribut
control
system
european
synchrotron
radiat
facil
esrf
automat
datacollect
system
track
sampl
control
crystal
mount
align
determin
experiment
strategi
base
initi
imag
collect
diffract
data
integr
scale
reduc
experiment
intens
sever
program
avail
build
ligand
electron
densiti
commerci
packag
includ
primex
new
york
ny
usa
rhofit
global
phase
cambridg
uk
afitt
openey
santa
fe
nm
usa
program
academ
laboratori
includ
coot
phenix
suit
arpwarp
autosolv
platform
develop
astex
therapeut
autom
xray
data
process
structur
solut
interpret
electron
densiti
map
ligand
fit
autosolv
implement
novel
fit
procedur
automat
determin
compound
ident
case
fragment
cocktail
bind
mode
best
explain
avail
electron
densiti
chemic
inform
form
favor
interact
target
account
histor
crystal
structur
model
result
one
worker
subject
interpret
electron
densiti
map
thu
use
xray
crystal
structur
fragment
screen
lead
design
nontrivi
depend
skill
crystallograph
strive
model
macromolecul
ligand
solvent
molecul
electron
densiti
accur
data
allow
autom
electron
densiti
map
provid
aforement
autosolv
platform
inher
object
unambigu
interpret
electron
densiti
map
produc
recogniz
shape
present
differ
map
section
describ
recent
case
cooper
bind
two
fragment
led
fals
posit
detect
everi
atom
structur
contain
atom
coordin
bfactor
temperatur
factor
model
static
dynam
disord
note
precis
coordin
report
regardless
resolut
resolut
lower
detail
protein
structur
eg
sidechain
placement
model
loop
may
ambigu
uncertainti
posit
individu
atom
could
resolut
even
moder
resolut
uncertainti
placement
asparagin
glutamin
histidin
occur
intern
pseudosymmetri
case
asparagin
glutamin
sidechain
n
atom
similar
electron
densiti
case
histidin
n
c
atom
imidazol
ring
usual
indistinguish
consequ
sidechain
residu
typic
built
two
orient
care
investig
account
ambigu
choos
conform
basi
hydrogenbond
donor
acceptor
surround
sidechain
residu
chang
solvent
structur
occur
due
ligand
bind
may
help
unravel
unusu
thermodynam
observ
interpret
solvent
bind
crystal
structur
becom
difficult
resolut
decreas
error
placement
ligand
includ
fragment
macromolecular
crystal
structur
aris
sever
caus
noncoval
bound
ligand
may
exhibit
greater
thermal
motion
conform
disord
surround
protein
lead
poor
electron
densiti
uncertainti
ambigu
stereochemistri
tautomer
state
ligand
may
also
lead
incorrect
model
fragment
intern
pseudosymmetri
consider
hydrogen
bond
hydrophob
etc
assist
interpret
ambigu
electron
densiti
exampl
locat
nitrogen
atom
pyridin
ring
ambigu
electron
densiti
alon
consid
similar
ambigu
note
placement
histidin
asparagin
glutamin
sidechain
note
structur
ligand
found
complex
biolog
molecul
may
less
reliabl
macromolecul
due
fact
model
build
valid
tool
macromolecular
structur
well
develop
compar
ligand
furthermor
geometr
constraint
bond
length
bond
angl
planar
chiral
restraint
appli
molecul
refin
thoroughli
optim
biolog
polym
compar
entiti
crystal
structur
model
program
eg
coot
abl
gener
geometr
restraint
ligand
base
smile
string
apart
pitfal
associ
accur
interpret
electron
densiti
artifact
may
gener
crystal
process
potenti
block
target
site
crystal
contact
result
falseneg
upon
soak
ligand
similarli
residu
surround
site
interest
could
held
inappropri
conform
ligand
bind
could
block
ligand
exampl
crystal
drug
target
lactos
dehydrogenas
appropri
soak
activ
site
loop
held
open
crystal
contact
substrat
site
occupi
citrat
crystal
buffer
phosphat
purif
buffer
addit
crystal
grown
extrem
ph
may
yield
ligandbind
mode
observ
physiolog
ph
due
protonationdeproton
suscept
sidechain
exampl
ph
proton
aspart
glutam
sidechain
signific
alter
charg
hydrogenbond
characterist
protein
structur
undergo
ph
depend
conform
chang
exampl
sever
acut
respiratori
syndrom
coronaviru
sarscov
main
proteas
show
substanti
differ
ph
amyloid
plaqu
associ
neurofibrillar
tangl
known
occur
brain
alzheim
diseas
ad
patient
plaqu
compos
peptid
deriv
amyloid
precursor
protein
activ
known
cleav
amyloid
precursor
protein
yield
nterminu
peptid
beta
aspartyl
proteas
respons
product
enzym
potenti
therapeut
target
treatment
ad
figur
show
bace
activ
site
complex
peptidomimet
inhibitor
murray
cowork
use
crystallographi
fb
librari
contain
fragment
screen
cocktail
contain
six
compound
two
hit
contain
aminopyridin
motif
found
form
hydrogen
bond
catalyt
aspart
residu
figur
b
hit
form
nearli
ident
interact
case
amin
group
form
hydrogen
bond
proton
pyridin
group
donat
hydrogen
bond
charg
bident
interact
describ
previous
aspartyl
proteas
hydrophob
pocket
adjac
ligand
essenti
substrat
peptid
bind
murray
cowork
sought
identifi
fragment
base
aminopyridin
motif
seen
figur
b
would
allow
access
region
dock
calcul
use
select
anoth
compound
screen
includ
focus
set
fragment
contain
motif
cyclic
secondari
amin
shown
interact
catalyt
aspart
residu
renin
also
select
compound
dock
multipl
protein
conform
use
modifi
version
gold
softwar
thu
fragment
rank
select
crystallograph
screen
benzylamino
pyridin
figur
found
bind
estim
bace
assay
util
fluoresc
label
peptid
interestingli
aminopyridin
moieti
compound
chang
orient
rel
fragment
hit
cf
figur
b
allow
addit
hydrogen
bond
group
cyclic
secondari
amin
piperidin
figur
also
identifi
virtual
screen
companion
paper
congrev
cowork
describ
synthesi
seri
deriv
view
make
compound
occupi
pocket
addit
block
catalyt
aspart
residu
phenyl
group
predict
make
suitabl
hydrophob
interact
region
compound
figur
synthes
mm
next
compound
synthes
indolesubstitut
aminopyridin
figur
display
favor
interact
pocket
compar
phenylsubstitut
compound
polar
interact
observ
indol
nh
carbonyl
oxygen
residu
greatli
improv
valu
indic
use
area
target
next
iter
design
deriv
synthes
includ
one
group
replac
indol
substitu
figur
also
made
favor
interact
pocket
biaryl
motif
judg
suitabl
modif
combin
biaryl
moieti
hit
benzylamino
pyridin
hit
figur
biaryl
substitut
synthes
better
fit
pocket
figur
group
introduc
compound
appear
form
favor
contact
pocket
best
compound
seri
npropyloxi
group
place
methoxi
group
figur
compound
consid
high
qualiti
lead
priorit
develop
compound
indolyl
group
substitut
ring
made
better
occupi
pocket
figur
indolyl
group
compound
occupi
pocket
form
new
hydrogen
bond
indolylnh
carbonyl
group
next
orthoposit
phenyl
ring
adjac
methylen
linker
target
view
occupi
subsit
two
ligand
made
contain
group
benzyloxi
group
figur
c
benzyloxycontain
compound
insolubl
allow
highqual
crystal
structur
determin
potent
inhibitor
nm
structur
show
evolut
fragment
hit
nanomolarinhibitor
compound
includ
bind
motif
previous
observ
aspart
proteas
inhibitor
aminopyridin
motif
interact
catalyt
aspart
residu
campdegrad
phosphodiesteras
famili
enzym
potenti
target
therapeut
treatment
chronic
obstruct
pulmonari
diseas
copd
asthma
depress
neurodegen
diseas
human
figur
difficult
crystal
make
screen
crystallographi
impract
recht
cowork
use
enthalpi
array
ie
array
nanocalorimet
perform
enzym
activitybas
fragment
screen
inhibitor
activ
fabric
enthalpi
array
measur
thermodynam
kinet
paramet
molecular
interact
describ
torr
cowork
array
use
small
sampl
volum
nl
short
assay
time
typic
min
possibl
convent
calorimetri
assay
use
base
hydrolysi
camp
measur
assay
valid
use
nonselect
phosphodiesteras
inhibitor
pentoxifyllin
figur
ibmx
initi
fragment
librari
screen
competit
inhibitor
calorimetr
data
chang
km
presenc
fragment
use
determin
ki
eleven
fragment
ki
valu
select
crystallographi
complex
fragment
obtain
cocrystal
diffract
qualiti
appar
depend
ligand
potenc
highqual
diffract
obtain
one
potent
ligand
pentoxifyllin
ki
figur
c
noteworthi
six
fragment
hit
contain
function
group
contain
purinelik
quinolinelik
featur
figur
natur
substrat
camp
contain
purin
ring
figur
known
pde
inhibitor
includ
methoxyphenyl
amino
methylsulfonyl
contain
quinolin
system
figur
although
possibl
obtain
crystal
structur
fragment
complex
pde
substrat
inhibitor
suggest
common
bind
mechan
wherebi
ligand
nitrogen
atom
accept
hydrogen
bond
activesit
residu
use
enthalpi
array
fragment
screen
sever
benefit
number
xray
structur
determin
reduc
may
necessit
structur
character
challeng
type
bind
competit
uncompetit
etc
elucid
human
phenylethanolamin
nmethyltransferas
hpnmt
catalys
last
step
adrenalin
synthesi
convers
noradrenalin
adrenalin
util
sadenosylmethionin
sam
methylgroup
donor
adrenalin
central
nervou
system
implic
rang
physiolog
patholog
condit
includ
parkinson
alzheim
diseas
pnmt
inhibitor
potenti
therapeut
valu
drinkwat
et
al
use
cocktail
four
fragment
total
compound
screen
hpnmt
crystallographi
cocktail
consid
fals
posit
examin
electron
densiti
fail
identifi
specif
fragment
densiti
observ
fragment
soak
crystal
separ
total
compound
ultim
identifi
bind
noradrenalinebind
site
itc
use
confirm
hit
compound
rule
subsequ
analysi
reveal
falseposit
hit
cocktail
soak
due
cooper
bind
nair
cowork
use
molecular
dynam
md
show
one
fals
posit
actual
two
fragment
cooper
bound
activesit
figur
show
compound
one
cocktail
use
soak
hpnmt
crystal
electron
densiti
initi
interpret
compound
figur
bind
could
valid
itc
nair
et
al
perform
md
simul
pnmt
complex
show
compound
eject
bind
pocket
ps
simul
seri
simul
reassess
electron
densiti
led
model
compound
shown
figur
b
bound
cooper
structur
correspond
structur
interpret
shown
figur
atp
depend
molecular
chaperon
modul
protein
stabil
key
compon
heatshock
respons
mani
client
protein
identifi
sever
involv
cellular
signal
eg
kinas
transcript
factor
play
critic
role
cancer
progress
overexpress
demonstr
cancer
type
advanc
malign
melanoma
oesophag
squamou
cell
carcinoma
nonsmal
cell
lung
cancer
pancreat
carcinoma
attract
target
chemotherapi
inhibit
activ
affect
multipl
signal
pathway
cellular
process
requir
cancer
cell
surviv
stress
furthermor
inhibitor
work
synergist
sever
drug
treatment
solid
tumor
leukemia
inhibit
small
molecul
popular
area
research
interest
last
decad
progress
made
diversifi
avail
chemotyp
murray
cowork
appli
fragmentbas
screen
use
nmr
itc
xray
crystallographi
compound
screen
cocktail
use
ligand
observ
nmr
via
waterlogsi
favor
compound
character
nmr
assay
measur
displac
fragment
adp
nucleotid
bind
site
base
nmr
assay
consider
structur
divers
fragment
select
crystallographi
result
crystal
structur
one
aminopyrimidin
compound
figur
measur
affin
estim
itc
pyrimidin
moieti
bind
structur
analog
way
purin
ring
adp
molecul
form
extens
network
hydrogen
bond
side
chain
water
molecul
develop
fragment
proceed
expans
compound
better
fill
lipophil
pocket
occupi
pyridin
moieti
reduct
intern
strain
due
torsion
angl
two
ring
crystal
structur
figur
show
pyridin
pyrimidin
ring
rotat
along
connect
bond
wherea
optim
geometri
system
close
structureact
relat
sar
analysi
quantum
mechan
calcul
torsion
contribut
subsequ
modif
led
compound
pyridin
ring
substitut
phenyl
group
methoxi
chloro
substitut
substitut
reliev
strain
better
fill
proxim
lipophil
pocket
ring
improv
occup
lipophil
pocket
solubl
compound
increas
order
improv
cellbas
activ
result
effort
incorpor
nethylmorpholinogroup
phenyl
ring
result
compound
shown
figur
nm
itc
estim
noteworthi
orient
compound
essenti
start
fragment
interact
maintain
similar
strategi
appli
phenolbas
fragment
hit
figur
itc
structur
complex
fragment
indic
methoxygroup
could
replac
substitu
occupi
proxim
lipophil
pocket
tertbutyl
isopropyl
group
posit
improv
affin
scaffold
substitut
advanc
synthet
effort
focus
diethylamid
group
carbonyl
group
kept
maintain
hydrogenbond
adjac
threonin
residu
adjac
water
molecul
isoindolin
group
replac
diethylamid
group
deliv
affin
improv
severalhundredfold
eventu
phenol
core
convert
resorcinol
core
due
similar
natur
product
radicicol
known
inhibitor
final
lead
figur
nm
itc
develop
drug
candid
clinic
trial
fbdd
flexibl
potent
tool
creation
small
molecul
potenti
develop
drug
coupl
highresolut
structur
complex
focus
strategi
medicin
chemistri
fragment
evolut
deriv
mani
possibl
workflow
design
fragment
screen
util
drug
discoveri
contemporari
effort
typic
use
one
biophys
method
thank
advanc
autom
softwar
robot
crystallographi
use
primari
screen
techniqu
determin
topolog
bind
fragment
target
protein
howev
determin
bind
affin
hit
techniqu
appli
gener
eas
access
synchrotron
radiat
attend
robot
infrastructur
make
approach
broadli
access
describ
four
case
crystallographi
contribut
fb
success
pitfal
highlight
case
inhibitor
crystallographi
straightforward
contribut
develop
nanomolar
case
crystallographi
challeng
screen
program
benefit
new
enthalpi
array
technolog
preselect
fragment
studi
final
fb
reveal
multipl
hit
gave
rise
altern
inhibitor
fb
hpnmt
demonstr
case
cooper
fragment
bind
diagnosi
md
simul
spite
disadvantag
describ
articl
crystallographi
play
central
role
structur
biolog
drug
discoveri
process
ultim
valu
xray
crystallographi
visual
fragment
bind
detail
indic
vector
expans
evolut
hit
orthogon
screen
techniqu
valu
rule
fals
posit
